CXXC5, especially cytosolic CXXC5, which binds Dvl, as a target for the development of drugs to treat NASH was confirmed by the similar improvement of NASH phenotypes in Cxxc5−/− mice and with oral application of KY19334, a small molecule interfering with CXXC5-Dvl protein‒protein interaction (PPI)24. The gene discussed is CXXC5; the disease is metabolic dysfunction-associated steatohepatitis.